Literature DB >> 29926373

Use of human-derived stem cells to create a novel, in vitro model designed to explore FMR1 CGG repeat instability amongst female premutation carriers.

Stephanie L F Gustin1, Guangwen Wang2, Valerie M Baker3, Gary Latham4, Vittorio Sebastiano5.   

Abstract

OBJECTIVE: Create a model, using reprogrammed cells, to provide a platform to identify the mechanisms of CGG repeat instability amongst female fragile X mental retardation 1 gene (FMR1) premutation (PM) carriers.
METHODS: Female PM carriers (with and without POI) and healthy controls were enrolled from June 2013 to April 2014. Patient-derived fibroblasts (FB) were reprogrammed to induced pluripotent stem cells (iPSC) using viral vectors, encoding KLF4, OCT4, SOX2, and MYC. FMR1 CGG repeat-primed PCR was used to assess the triplet repeat structure of the FMR1 gene. FMR1 promoter methylation (%) was determined using FMR1 methylation PCR (mPCR). Quantification of FMR1 transcripts by RT-qPCR was used to evaluate the effect of reprogramming on gene transcription, as well as to correlate patient phenotype with FMR1 expression. Production of FMR1 protein (FMRP) was determined using a liquid bead array-based immunoassay.
RESULTS: Upon induction to pluripotency, all control clones exhibited maintenance of progenitor cell CGG repeat number, whereas 10 of 12 clones derived from PM carriers maintained their input CGG repeat number, one of which expanded and one contracted. As compared to parent FB, iPSC clones exhibited a skewed methylation pattern; however, downstream transcription and translation appeared unaffected. Further, the PM carriers, regardless of phenotype, exhibited similar FMR1 transcription and translation to the controls.
CONCLUSIONS: This is the first study to establish a stem cell model aimed to understand FMR1 CGG repeat instability amongst female PM carriers. Our preliminary data indicate that CGG repeat number, transcription, and translation are conserved upon induction to pluripotency.

Entities:  

Keywords:  CGG repeat; FMR1; Premutation; Primary ovarian insufficiency; Stem cell; iPSC

Mesh:

Substances:

Year:  2018        PMID: 29926373      PMCID: PMC6086796          DOI: 10.1007/s10815-018-1237-y

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  40 in total

Review 1.  FMR1 and the continuum of primary ovarian insufficiency.

Authors:  Shannon D Sullivan; Corrine Welt; Stephanie Sherman
Journal:  Semin Reprod Med       Date:  2011-10-03       Impact factor: 1.303

2.  Stem cells and drug discovery: the beginning of a new era?

Authors:  Lee L Rubin
Journal:  Cell       Date:  2008-02-22       Impact factor: 41.582

3.  Ovarian abnormalities in a mouse model of fragile X primary ovarian insufficiency.

Authors:  Gloria E Hoffman; Wei Wei Le; Ali Entezam; Noriyuki Otsuka; Zhi-Bin Tong; Lawrence Nelson; Jodi A Flaws; John H McDonald; Sanjeeda Jafar; Karen Usdin
Journal:  J Histochem Cytochem       Date:  2012-04-02       Impact factor: 2.479

4.  Association of FMR1 repeat size with ovarian dysfunction.

Authors:  A K Sullivan; M Marcus; M P Epstein; E G Allen; A E Anido; J J Paquin; M Yadav-Shah; S L Sherman
Journal:  Hum Reprod       Date:  2004-12-17       Impact factor: 6.918

5.  Induced expression of expanded CGG RNA causes mitochondrial dysfunction in vivo.

Authors:  Renate K Hukema; Ronald A M Buijsen; Chris Raske; Lies Anne Severijnen; Ingeborg Nieuwenhuizen-Bakker; Michelle Minneboo; Alex Maas; Rini de Crom; Johan M Kros; Paul J Hagerman; Robert F Berman; Rob Willemsen
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

6.  A novel FMR1 PCR method for the routine detection of low abundance expanded alleles and full mutations in fragile X syndrome.

Authors:  Stela Filipovic-Sadic; Sachin Sah; Liangjing Chen; Julie Krosting; Edward Sekinger; Wenting Zhang; Paul J Hagerman; Timothy T Stenzel; Andrew G Hadd; Gary J Latham; Flora Tassone
Journal:  Clin Chem       Date:  2010-01-07       Impact factor: 8.327

7.  Generation of human-induced pluripotent stem cells.

Authors:  In-Hyun Park; Paul H Lerou; Rui Zhao; Hongguang Huo; George Q Daley
Journal:  Nat Protoc       Date:  2008       Impact factor: 13.491

8.  Analysis of FMR1 gene expression in female premutation carriers using robust segmented linear regression models.

Authors:  Eva García-Alegría; Berta Ibáñez; Mónica Mínguez; Marisa Poch; Alberto Valiente; Arantza Sanz-Parra; Cristina Martinez-Bouzas; Elena Beristain; Maria-Isabel Tejada
Journal:  RNA       Date:  2007-05       Impact factor: 4.942

9.  Fate of induced pluripotent stem cells following transplantation to murine seminiferous tubules.

Authors:  Jens Durruthy Durruthy; Cyril Ramathal; Meena Sukhwani; Fang Fang; Jun Cui; Kyle E Orwig; Renee A Reijo Pera
Journal:  Hum Mol Genet       Date:  2014-01-20       Impact factor: 6.150

10.  Epigenetic characterization of the FMR1 promoter in induced pluripotent stem cells from human fibroblasts carrying an unmethylated full mutation.

Authors:  Celine E F de Esch; Mehrnaz Ghazvini; Friedemann Loos; Nune Schelling-Kazaryan; W Widagdo; Shashini T Munshi; Erik van der Wal; Hannie Douben; Nilhan Gunhanlar; Steven A Kushner; W W M Pim Pijnappel; Femke M S de Vrij; Niels Geijsen; Joost Gribnau; Rob Willemsen
Journal:  Stem Cell Reports       Date:  2014-09-11       Impact factor: 7.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.